Test Type: TOX

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

Study Number:

Study Gender:

PWG Approval Date:

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

C11049-01

Male

See web page for date of PWG Approval

Date Report Requested: 10/22/2020 Time Report Requested: 09:33:45

Test Type: TOX

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane **CAS Number:** 18107-18-1

Time Report Requested: 09:33:45 Lab: Battelle with CRL

Date Report Requested: 10/22/2020

Male: 1 Day Exposure

	Treatment Groups (ppm)			
	0	10	25 ppm Hexanes	
Disposition Summary				
Animals Initially In Study	8	8	8	
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (SD 1)	8	8	8	
Number of Animals Examined	8	8	8	
ALIMENTARY SYSTEM				
LIVER	(8)	(8)	(8)	
HEMATOPOIETIC CELL PROLIFERATION		1 (12.5%)		
PHARYNX	(8)	(8)	(8)	
HYPERPLASIA; SQUAMOUS		1 (12.5%)		
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
None				
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				

Test Type: TOX

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Date Report Requested: 10/22/2020 Time Report Requested: 09:33:45

Male: 1 Da	y Exposure
------------	------------

	Treatment Groups (ppm)			
	0	10	25 ppm Hexanes	
MUSCULOSKELETAL SYSTEM None				
NERVOUS SYSTEM None				
RESPIRATORY SYSTEM				
LARYNX	(7)	(8)	(8)	
EPIGLOTTIS; INFLAMMATION		1 (12.5%)		
INFLAMMATION; CHRONIC-ACTIVE	1 (14.3%)			
EPIGLOTTIS; METAPLASIA; SQUAMOUS		1 (12.5%)		
LUNG	(8)	(8)	(8)	
ERYTHROPHAGOCYTOSIS		1 (12.5%)		
HEMORRHAGE; ACUTE	1 (12.5%)	1 (12.5%)		
INFILTRATION, CELLULAR; MIXED		1 (12.5%)		
TRACHEA	(8)	(8)	(8)	
EPITHELIUM; DEGENERATION		1 (12.5%)		
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
KIDNEY, LEFT	(8)	(8)	(8)	
INFILTRATE, CELLULAR; MIXED		1 (12.5%)	2 (25%)	
NEPHROPATHY	2 (25%)	3 (37.5%)	1 (12.5%)	

Test Type: TOX

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane **CAS Number:** 18107-18-1

Date Report Requested: 10/22/2020 Time Report Requested: 09:33:45

Lab: Battelle with CRL

Male: 1 Day Recovery

	Treatment Groups (ppm)			
	0	10	25 ppm Hexanes	
Disposition Summary				
Animals Initially In Study	8	8	8	
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (SD 9)	8	8	8	
Number of Animals Examined	8	8	8	
ALIMENTARY SYSTEM				
LIVER	(8)	(8)	(8)	
CLEAR CELL FOCUS		1 (12.5%)		
HEMATOPOIETIC CELL PROLIFERATION			1 (12.5%)	
HEPATODIAPHRAGMATIC NODULE	1 (12.5%)			
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
None				
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

Test Type: TOX

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Date Report Requested: 10/22/2020 Time Report Requested: 09:33:45

Lab: Battelle with CRL

Male: 1 Day Recovery

		Treatment Groups (ppm)			
	0	10	25 ppm Hexanes		
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
LUNG	(8)	(8)	(8)		
HEMORRHAGE; ACUTE		1 (12.5%)			
PERIVASCULAR; INFILTRATION, CELLULAR; MIXED			2 (25%)		
NOSE	(8)	(8)	(8)		
GOBLET CELL; HYPERPLASIA		1 (12.5%)			
INFLAMMATION; LYMPHOHISTIOCYTIC			1 (12.5%)		
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
KIDNEY, LEFT	(8)	(8)	(8)		
NEPHROPATHY	7 (87.5%)	3 (37.5%)	3 (37.5%)		

Test Type: TOX

None

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane **CAS Number:** 18107-18-1

Time Report Requested: 09:33:45

Date Report Requested: 10/22/2020

	ıv.	Male : 5 Day Exposi	ui C					
	Treatment Groups (ppm)							
	0	0.3	1	3	10	25 ppm Hexanes		
Disposition Summary								
Animals Initially In Study	8	8	8	8	8	8		
Early Deaths								
Scheduled Deaths								
Scheduled sacrifice, terminal (SD 5)	8	8	8	8	8	8		
Number of Animals Examined	8		8	8	8	8		
ALIMENTARY SYSTEM								
LIVER	(8)	(0)	(0)	(0)	(8)	(8)		
HEMATOPOIETIC CELL PROLIFERATION					1 (12.5%)	1 (12.5%)		
CARDIOVASCULAR SYSTEM								
None								
ENDOCRINE SYSTEM								
None								
GENERAL BODY SYSTEM								
None								
GENITAL SYSTEM								
None								
HEMATOLYMPHOID SYSTEM								
LYMPH NODE, MEDIASTINAL	(8)	(0)	(7)	(8)	(8)	(8)		
LYMPHOID TISSUE; HYPERPLASIA			2 (28.6%)			1 (12.5%)		
INFILTRATION, CELLULAR; HISTIOCYTE	0 **			1 (12.5%)	8 (100%) **	2 (25%)		
INTEGUMENTARY SYSTEM								

Test Type: TOX

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane **CAS Number:** 18107-18-1

Date Report Requested: 10/22/2020 Time Report Requested: 09:33:45

Male	:	5	Day	Exp	osui	e
------	---	---	-----	-----	------	---

Miale . 3 Day Exposure							
	Treatment Groups (ppm)						
	0	0.3	1	3	10	25 ppm Hexanes	
MUSCULOSKELETAL SYSTEM None							
NERVOUS SYSTEM None							
RESPIRATORY SYSTEM							
LARYNX EPITHELIAL CELL; HYPERPLASIA; SQUAMOUS EPIGLOTTIS; METAPLASIA; SQUAMOUS	(8)	(0)	(0)	(0)	(8) 2 (25%) 2 (25%)	(8)	
LUNG EDEMA	(8) 0 **	(0)	(8)	(8)	(8) 7 (87.5%) **	(8)	
INTERSTITIUM; FIBROSIS HEMORRHAGE; ACUTE	0 ** 0 ** 0 **			C /7F0/\ **	8 (100%) ** 8 (100%) **		
ALVEOLAR EPITHELIUM; HYPERPLASIA BRONCHIOLE EPITHELIUM; HYPERPLASIA INFILTRATION, CELLULAR; HISTIOCYTE	0 **			6 (75%) ** 7 (87.5%) ** 7 (87.5%) **	8 (100%) ** 8 (100%) **		
INFLAMMATION; CHRONIC-ACTIVE INFLAMMATION; CHRONIC-ACTIVE, FOCAL	0 **		2 (25%)	7 (87.5%) **	8 (100%) **		
TRACHEA EPITHELIUM; DEGENERATION	(8)	(0)	(0)	(0)	(8)	(8) 1 (12.5%)	
SPECIAL SENSES SYSTEM None							
URINARY SYSTEM							
KIDNEY, LEFT NEPHROPATHY	(8) 3 (37.5%)	(0)	(0)	(0)	(8)	(8) 2 (25%)	

Test Type: TOX

None

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Test Compound: Trimethylsilyldiazomethane **CAS Number:** 18107-18-1

Lab: Battelle with CRL

Date Report Requested: 10/22/2020

Time Report Requested: 09:33:45

Male	:	5	Day	Reco	very
------	---	---	-----	------	------

	Treatment Groups (ppm)						
	0	0.3	1	3	10	25 ppm Hexane	
Disposition Summary							
Animals Initially In Study	8	8	8	8	8	8	
Early Deaths							
Scheduled Deaths							
Scheduled sacrifice, terminal (SD 9)	8	8	8	8	8	8	
Number of Animals Examined	8	8	8	8	8	8	
ALIMENTARY SYSTEM							
None							
CARDIOVASCULAR SYSTEM							
None							
ENDOCRINE SYSTEM							
None							
GENERAL BODY SYSTEM							
None							
GENITAL SYSTEM							
None							
HEMATOLYMPHOID SYSTEM							
LYMPH NODE, MEDIASTINAL	(8)	(0)	(8)	(8)	(8)	(8)	
LYMPHOID TISSUE; HYPERPLASIA	1 (12.5%)		2 (25%)	2 (25%)	2 (25%)	1 (12.5%)	
INFILTRATION, CELLULAR; HISTIOCYTE	1 (12.5%) **			5 (62.5%)	8 (100%) **		

Test Type: TOX

URINARY SYSTEM KIDNEY, LEFT

NEPHROPATHY

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Date Report Requested: 10/22/2020 Time Report Requested: 09:33:45

Lab: Battelle with CRL

	Treatment Groups (ppm)						
	0	0.3	1	3	10	25 ppm Hexane	
MUSCULOSKELETAL SYSTEM							
None							
NERVOUS SYSTEM							
None							
RESPIRATORY SYSTEM							
LARYNX	(8)	(0)	(0)	(0)	(8)	(8)	
INFILTRATION, CELLULAR; MIXED						2 (25%)	
LUNG	(8)	(8)	(8)	(8)	(8)	(8)	
EDEMA	0 **				7 (87.5%) **		
INTERSTITIUM; FIBROSIS	0 **				8 (100%) **		
HEMORRHAGE; ACUTE	0 **	1 (12.5%)	1 (12.5%)	3 (37.5%)	8 (100%) **		
ALVEOLAR EPITHELIUM; HYPERPLASIA	0 **		1 (12.5%)	2 (25%)	8 (100%) **		
BRONCHIOLE EPITHELIUM; HYPERPLASIA	0 **				6 (75%) **		
INFILTRATION, CELLULAR; HISTIOCYTE		1 (12.5%)	2 (25%)	8 (100%) **			
INFLAMMATION; CHRONIC-ACTIVE	0 **		2 (25%)	8 (100%) **	8 (100%) **		
INFLAMMATION; CHRONIC-ACTIVE, FOCAL	1 (12.5%)	3 (37.5%)				1 (12.5%)	
NOSE	(8)	(0)	(0)	(0)	(8)	(8)	
INFILTRATION, CELLULAR; NEUTROPHIL					2 (25%)		
INFLAMMATION; CHRONIC						1 (12.5%)	
TRACHEA	(8)	(0)	(0)	(0)	(8)	(8)	
EPITHELIUM; DEGENERATION					1 (12.5%)		

(0)

(0)

(8)

6 (75%)

(8)

1 (12.5%)

(0)

(8)

2 (25%)

Test Type: TOX

Route: Nose-Only Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA10X: Statistical Analysis of Non-Neoplastic Lesions

CAS Number: 18107-18-1

Test Compound: Trimethylsilyldiazomethane

Lab: Battelle with CRL

Date Report Requested: 10/22/2020

Time Report Requested: 09:33:45

LEGEND

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number of animals with observation reported with percent incidence in parentheses

Statistical analysis performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) tests.

Statistical analysis for the negative control group compared to the vehicle control group was performed using the Fisher Exact test.

Trend significance is reported only for those organs that were fully examined in the control group plus two or more other dose groups. For organs that were fully examined in just the control and one other dose group, only the pairwise significance is reported.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

All trend and pairwise p-values are reported as one-sided.

- * Statistically significant at P <= 0.05
- ** Statistically significant at P <= 0.01

The 1 Day Exposure animals were exposed for one day and then sacrificed on study day 1 (first day of exposure was study day 0); the 1 Day Recovery animals were exposed for 1 day and then sacrificed on study day 9; the 5 Day Exposure animals were exposed for five days and then sacrificed on study day 5; the 5 Day Recovery animals were exposed for five days and then sacrificed on study day 9.

** END OF REPORT **